Comparison of the Efficacy of EGFR-TKIs Combined with Antiangiogenic Agents between Patients with Exon 19 Deletion and Patients with Exon 21 Leu858 Arg Mutation: A Systematic Review and Meta-Analysis

Table 1

Baseline characteristics of included studies.

Trials	Authors	Source (year)	Region	Study type	Study population	Treatments	Sample size		Primary endpoint
							Exon 19 deletion	Exon 21 Leu858 Arg mutation
JO25567	Seto et al.	Lancet Oncol	Japan	Phase 2 RCT	IIIB/IV or recurrent	Erlotinib 150 mg/d	40	37	PFS
		2014				Erlotinib 150 mg/d + bevacizumba 15 mg/kg Q3w	40	35
NEJ026	Saito et al.	Lancet Oncol	Japan	Phase 3 RCT	IIIB/IV or recurrent	Erlotinib 150 mg/d	55	57	PFS
		2019				Erlotinib 150 mg/d + bevacizumba 15 mg/kg Q3w	56	56
RELAY	Nakagawa et al.	Lancet Oncol	Worldwide	Phase 3 RCT	IV or recurrent	Erlotinib 150 mg/d	120	105	PFS
		2019				Erlotinib 150 mg/d + ramucirumab 10 mg/kg Q2w	123	99
NCT01532089	Stinchcombe et al.	JAMA Oncol	USA	Phase 2 RCT	IV	Erlotinib 150 mg/d	30	15	PFS
		2019				Erlotinib 150 mg/d + bevacizumba 15 mg/kg Q3w	29	14
ARTEMIS	Zhou et al.	Cancer cell	China	Phase 3 RCT	IIIB/IV or recurrent	Erlotinib 150 mg/d	79	75	PFS
		2021				Erlotinib 150 mg/d + bevacizumba 15 mg/kg Q3w	82	75
ACTIVE	Zhao et al.	J thorac Oncol	China	Phase 3 RCT	IIIB/IV	Gefitinib 250 mg/d	83	73	PFS
		2021				Gefitinib 250 mg/d + apatinib 500 mg/d	81	74

RCT: randomized controlled trial. PFS: progression-free survival.